Repros Therapeutics Inc. (NASDAQ:RPRX) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.24, Bloomberg Earnings reports. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%.

Repros Therapeutics (NASDAQ:RPRX) opened at $0.41 on Tuesday. Repros Therapeutics has a twelve month low of $0.26 and a twelve month high of $2.15.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/14/repros-therapeutics-inc-rprx-issues-earnings-results-beats-estimates-by-0-24-eps.html.

Separately, Laidlaw downgraded shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Earnings History for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.